- Home
- GENK vs BFRI Comparison
GENK vs BFRI Comparison
Compare GENK & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | BFRI |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | 2700 | 94 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 13.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENK | BFRI |
|---|---|---|
| Price | $1.95 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $4.50 | $2.75 |
| AVG Volume (30 Days) | 18.3K | ★ 229.6K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $4.79 | $14.36 |
| Revenue Next Year | $7.48 | $16.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.43 | $0.57 |
| 52 Week High | $4.98 | $1.19 |
Technical Indicators
Market Signals| Indicator | GENK | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 55.42 |
| Support Level | $1.72 | $1.00 |
| Resistance Level | $2.31 | $1.12 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 8.97 | 58.06 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.